| First Author | Karantanos T | Year | 2013 |
| Journal | Cancer Cell | Volume | 24 |
| Issue | 1 | Pages | 11-3 |
| PubMed ID | 23845440 | Mgi Jnum | J:199223 |
| Mgi Id | MGI:5501345 | Doi | 10.1016/j.ccr.2013.06.007 |
| Citation | Karantanos T, et al. (2013) GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer. Cancer Cell 24(1):11-3 |
| abstractText | Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance. |
